Journal article
NCIC CTG IND.122: a phase I/II pharmacokinetics (PK) and pharmacodynamic (PD) study of zd1839 (iressa ‘TM’). Final phase I results and preliminary phase II results of ZD1839 (750 mg/day) in patients (pts) with colorectal cancer
Authors
Goss G; Hirte H; Batist G; Miller W; Stewart D; Matthews S; Seymour L
Journal
European Journal of Cancer, Vol. 37, ,
Publisher
Elsevier
Publication Date
April 1, 2001
DOI
10.1016/s0959-8049(01)81559-8
ISSN
0959-8049